“No More Metal”: Cordis’ Selution SLR Wins Landmark FDA Approval as First U.S. Sirolimus Drug-Coated Balloon

The U.S. Food and Drug Administration (FDA) has granted pre-market approval to Cordis’ Selution SLR, establishing it as the first sirolimus-eluting balloon (DEB/DCB) cleared for commercial use in the United States.

Approved specifically for the treatment of coronary in-stent restenosis (ISR), the device introduces a practical “leave nothing behind” (no more metal) treatment option for interventional cardiologists. Instead of deploying another permanent metallic drug-eluting stent (DES) inside a vessel that has re-narrowed, clinicians can inflate the balloon to dilate the lesion, deliver micro-reservoirs of the anti-proliferative drug sirolimus into the arterial wall, and withdraw the device—leaving no new permanent foreign metal scaffold behind.

Key Takeaways

First FDA-Approved Sirolimus Balloon: Selution SLR is the first sirolimus-coated balloon approved by the US FDA, breaking the long-standing regulatory monopoly of paclitaxel-based balloon platforms in the domestic market.
Indication for In-Stent Restenosis (ISR): Indicated to treat coronary in-stent restenosis—where a previously placed coronary stent clogs due to scar tissue growth (neointimal hyperplasia).
The “No More Metal” Advantage: Eliminates the need to layer permanent stents on top of older stents (“full-metal jacket”), reducing risks of chronic inflammation, vessel rigidity, and secondary thrombosis.
Proprietary Micro-Reservoir Release: Uses biodegradable polymer micro-reservoirs loaded with sirolimus that embed into the vessel tissue during standard balloon inflation, providing sustained drug release over 90 days.
Clinical Trial Backing: Supported by the pivotal SELUTION DeNovo and ISR clinical data demonstrating non-inferiority compared to standard-of-care repeat drug-eluting stenting regimens.
Cordis / MedAlliance Pedigree: Cordis (which pioneered the first FDA-approved sirolimus drug-eluting stent, CYPHER, in 2003) acquired Swiss medtech firm MedAlliance in a $235 million transaction to bring Selution SLR to the US market.

1. Central Question: Why Does a “No More Metal” Sirolimus Balloon Matter?

Direct Answer: When a coronary artery narrows again after a stent is implanted (in-stent restenosis), the standard response for decades has been to deploy a second (or third) stent inside the original cage. This progressive layering of metal permanently damages natural arterial compliance, triggers chronic vascular inflammation, and significantly raises the lifetime risk of target vessel failure.

While Boston Scientific’s Agent drug-coated balloon secured FDA clearance in 2024 using paclitaxel, many interventional cardiologists have long preferred sirolimus. Sirolimus features a broader therapeutic safety window, lower systemic cytotoxicity, and identical drug biology to the contemporary drug-eluting stents cardiologists use daily. Selution SLR delivers the familiar anti-restenotic pharmacology of sirolimus without leaving a permanent metallic cage behind.

                         THE IN-STENT RESTENOSIS TREATMENT PARADIGM
                                             │
        ┌────────────────────────────────────┴────────────────────────────────────┐
        ▼                                                                         ▼
CONVENTIONAL REPEAT STENTING (DES)                              SELUTION SLR DRUG BALLOON (NO METAL)
• Adds a 2nd or 3rd layer of permanent metallic struts          • Inflates to reopen artery; transfers micro-reservoirs
• Reduces vessel elasticity and creates "metal jacket"          • Device is completely withdrawn from patient body
• High cumulative risk of late-stage stent thrombosis           • Leaves native vessel anatomy free of added foreign bodies
• Hinders future bypass or emergency catheter re-entry          • Preserves future clinical interventions and CABG options
        │                                                                         │
        └────────────────────────────────────┬────────────────────────────────────┘
                                             ▼
                             SUSTAINED SIROLIMUS RELEASE
                    Polymer micro-reservoirs embed into vessel tissue,
                   eluting sirolimus over 90 days to block scar tissue.

2. Technical Profile: How Selution SLR Delivers Sirolimus

Unlike paclitaxel—which is lipophilic and binds rapidly to arterial walls—sirolimus is more difficult to deliver effectively via an instantaneous balloon inflation without washing away in the bloodstream. Selution SLR overcomes this with a proprietary drug-delivery architecture:

+-----------------------------------------------------------------------------------+
|               CORDIS SELUTION SLR: TECHNICAL & REGULATORY SNAPSHOT                |
+-----------------------------------------------------------------------------------+
| Technical Dimension            | Engineering & Clinical Specification             |
+--------------------------------+---------------------------------------------------+
| **Active Pharmaceutical Agent**| **Sirolimus** (mTOR inhibitor anti-proliferative) |
| **Delivery Vehicle**           | Biodegradable PLGA Polymer Micro-Reservoirs       |
| **Release Kinetics**           | Controlled sustained elution over **90+ Days**    |
| **Balloon Type**               | Semi-compliant rapid exchange (RX) PTCA catheter  |
| **Primary Indication**         | Coronary In-Stent Restenosis (ISR)                |
| **Regulatory Precedents**      | CE Mark (Europe) / US FDA Pre-Market Approval     |
| **Acquisition Origin**         | Developed by MedAlliance ($235M Cordis buyout)    |
+--------------------------------+---------------------------------------------------+

                          HOW MICRO-RESERVOIR TECHNOLOGY WORKS
                                           │
                                           ▼
                       1. CATHETER POSITIONED AT ISR LESION
                     Navigated through guide catheter over 0.014" wire
                                           │
                                           ▼
                      2. LOW-PRESSURE INFLATION (30–60 SECONDS)
                  Balloon wall contacts neointimal hyperplasia plaque
                                           │
                                           ▼
                     3. MICRO-RESERVOIR TRANSFER & EMBEDMENT
                 Micro-spheres of sirolimus + polymer lodge into tissue
                                           │
                                           ▼
                     4. BALLOON DEFLATION AND FULL REMOVAL
                   Catheter withdrawn; zero metal remains in artery
                                           │
                                           ▼
                     5. 90-DAY CONTROLLED DRUG ELUTION
                  Inhibits smooth muscle proliferation (restenosis)

Biodegradable Micro-Reservoirs: The balloon surface is coated with micro-reservoirs constructed from a biocompatible, biodegradable polymer (poly-lactic-co-glycolic acid, or PLGA) encapsulating sirolimus.
Cellular Adhesion: During a standard 30- to 60-second balloon dilatation, the micro-reservoirs transfer from the balloon surface and embed directly into the cellular tissue of the arterial wall.
Controlled Elution: Once embedded, the micro-reservoirs slowly hydrolyze, releasing sirolimus over a controlled 90-day window—the critical time frame when vascular smooth-muscle cells proliferate to form in-stent scar tissue.

3. Competitive Landscape: Paclitaxel vs. Sirolimus Drug Balloons

The US interventional cardiology market has historically lagged behind Europe and Asia in adopting drug-coated balloons, largely due to regulatory hurdles at the FDA regarding paclitaxel safety signals:

+-----------------------------------------------------------------------------------+
|               U.S. CORONARY DRUG BALLOON REVOLUTION: HEAD-TO-HEAD                 |
+-----------------------------------------------------------------------------------+
| Feature / Metric               | Boston Scientific AGENT  | Cordis SELUTION SLR   |
+--------------------------------+--------------------------+-----------------------+
| **Active Drug**                | Paclitaxel               | **Sirolimus**         |
| **FDA Approval Timing**        | Early 2024               | **Late 2026**         |
| **Mechanism of Action**        | Microtubule stabilization| mTOR receptor inhibitor|
| **Therapeutic Window**         | Narrow (Cytotoxic)       | **Wide (Cytostatic)** |
| **Control Group in Trial**     | Uncoated balloon         | **Standard of Care DES**|
| **Global Clinical Preference** | Historical standard      | **Modern consensus pick**|
+--------------------------------+--------------------------+-----------------------+

The Stent Habit: In the United States, interventional cardiologists have relied on drug-eluting stents for over two decades. When treating in-stent restenosis, guidelines historically favored repeat stenting because uncoated plain balloons frequently failed.
Breaking the “Stent in Stent” Cycle: With Selution SLR proven non-inferior against active stenting controls, cath labs gain a viable tool to treat multi-layer restenosis without forcing patients into high-risk bypass surgery.

Frequently Asked Questions (FAQs)

What is the Cordis Selution SLR?

Selution SLR is an angioplasty balloon catheter coated with biodegradable micro-reservoirs of the drug sirolimus. It is the first sirolimus-eluting balloon approved by the US FDA to treat coronary in-stent restenosis.

What does “No more metal” mean in cardiac treatment?

“No more metal” refers to treating blocked coronary arteries without leaving a permanent metallic wire mesh stent in the patient’s body. The balloon temporarily expands the artery, transfers medication to the vessel walls to stop scar tissue growth, and is then completely removed.

How does sirolimus differ from paclitaxel on drug-coated balloons?

Paclitaxel is a cytotoxic agent that stops cell division by freezing microtubules, while sirolimus is an immunosuppressive cytostatic agent that inhibits the mTOR pathway. Cardiologists often favor sirolimus because it has a wider therapeutic safety margin and is the standard drug used on modern drug-eluting stents.

What condition is Selution SLR approved to treat?

The FDA approval specifically covers coronary in-stent restenosis (ISR)—a condition where scar tissue forms inside a previously placed cardiac stent, narrowing the artery again.